Leflunomide considered safe, effective for psoriatic arthritis

October 14, 2012
Leflunomide considered safe, effective for psoriatic arthritis
Leflunomide is effective for the treatment of patients with psoriatic arthritis in daily clinical practice, according to a study published online Oct. 6 in Arthritis Care & Research.

(HealthDay)—Leflunomide is effective for the treatment of patients with psoriatic arthritis (PsA) in daily clinical practice, according to a study published online Oct. 6 in Arthritis Care & Research.

To assess the effectiveness and safety of leflunomide, Frank Behrens, M.D., from Johann Wolfgang Goethe-University in Frankfurt, Germany, and colleagues conducted a prospective, multinational 24-week observational study involving 514 adult patients (mean age, 50.7 years; mean disease duration, 6.1 years) with active PsA who began treatment with leflunomide. The Response Criteria (PsARC) was used to assess response.

The researchers found that, in the primary effectiveness analysis, at 24 weeks, 380 of 440 patients (86.4 percent) achieved a PsARC response. Tender and swollen joint scores and counts improved significantly, as did patient and physician global assessments, fatigue, pain, skin disease, dactylitis, and nail lesions. The rate of treatment discontinuation was 12.3 percent. Adverse drug reactions occurred in 62 patients (12.1 percent), with three considered serious (two increased liver enzymes and one hypertensive crisis).

"On the basis of these data, we conclude that leflunomide is effective and has a favorable safety profile in the therapy of PsA in daily clinical practice," the authors write. "Its ability to alleviate joint, skin, and other disease manifestations; manageable safety profile; and relatively low price make leflunomide a valuable option for the treatment of ."

Several authors disclosed financial ties to sanofi-aventis, which funded the study.

Explore further: Rheumatoid arthritis drug not linked to specific birth defects

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Recommended for you

Cross-species links identified for osteoarthritis

May 17, 2017

New research from the University of Liverpool, published today in the journal npj Systems Biology and Applications, has identified 'cell messages' that could help identify the early stages of osteoarthritis (OA).

Anti-hypertension DASH diet may reduce the risk of gout

May 9, 2017

The results of a study led by Massachusetts General Hospital (MGH) investigators suggest that following a diet known to reduce the risk of hypertension and cardiovascular disease may also reduce the risk of gout. The team's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.